| アイテムタイプ |
学術雑誌掲載論文(1) |
| 公開日 |
2025-09-30 |
| タイトル |
|
|
タイトル |
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 著者 |
Kanamori Masayuki
Shibahara Ichiyo
Shimoda Yoshiteru
Akiyama Yukinori
Beppu Takaaki
Ohba Shigeo
Enomoto Toshiyuki
Ono Takahiro
Mitobe Yuta
Hanihara Mitsuto
Mineharu Yohei
Ishida Joji
Asano Kenichiro
Yoshida Yasuyuki
Natsumeda Manabu
Nomura Sadahiro
Abe Tatsuya
Yonezawa Hajime
Katakura Ryuichi
Shibui Soichiro
Kuroiwa Toshihiko
Suzuki Hiroyoshi
Takei Hidehiro
Matsushita Haruo
Saito Ryuta
Arakawa Yoshiki
Sonoda Yukihiko
Hirose Yuichi
Kumabe Toshihiro
Yamaguchi Takuhiro
Endo Hidenori
Tominaga Teiji
|
| キーワード |
|
|
言語 |
en |
|
主題 |
Bevacizumab, Carmustine wafers, Glioblastoma, Maximal resection, Temozolomide |
| 識別子 |
|
|
識別子 |
https://doi.org/10.1007/s10147-024-02650-9 |
|
識別子タイプ |
DOI |
| 書誌情報 |
en : International journal of clinical oncology
巻 30,
号 1,
p. 51-61,
ページ数 11,
発行日 2024-11-11
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1437-7772 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 権利情報 |
|
|
権利情報 |
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |